Dublin, May 29, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Gastro Esophageal Reflux Disease (GERD) Drug and Devices Market - Analysis and Forecast 2017-2023 (Focus on Device Type, Drug Type, Market Share Analysis, Patent Landscape and Country Analysis)" report to their offering.
The GERD market is mainly driven by the dearth of treatment options. Most of the blockbuster drugs have gone off patent paving way for the generic & OTC products in the market. Due to low safety, efficacy & poor reimbursement of devices & procedures, these are not popular among physicians & patients alike. The lack of new regulatory approved medication as well as limited acceptability of devices are the major limitations of the market.
The drug market is occupied by generics & OTC products. By drug class, the market can be classified into antacids, proton pump inhibitors (PPI), histamine-2 receptor blockers (H2RA), prokinetics & complementary & alternative medicines. The antacid class has the largest market share as they provide quick relief and are available over-the-counter. The PPIs constitute the next major market share & are the first line treatment in moderate to severe GERD. H2RA are also prescribed in combination with PPIs or alone where required. The long term use of PPIs is associated with increased risk of bone fractures, low magnesium absorption, C.difficile infections etc. This is prompting patients to look for other treatment options.
With the advent of generics & OTC products the growth in GERD drugs market has decreased. The absence of patent protected & new regulatory approved medicines are the restraints for the growth of this market. The global GERD drugs market has a low growth potential in future and will account to $5.38 billion by 2023. Due to side effects of drugs on long term use, patients who fail to respond to medication & the availability of new technology, the device market is set to grow in future.
The market is dominated by drugs as they are the first line treatment for the early & mild cases of GERD. But the number of drugs in the pipeline are less & market is well established in the drugs segment. The GERD Therapy Market is divided into drugs & devices segment based on product type. The drugs segment is an established market offering antacids, PPIs, H2RAs & prokinetics. The drugs market will not show much growth in future due to loss of patent protection & absence of novel treatment options.
The device segment is growing at a CAGR of 15.3% from 2017 to 2023. The devices can be categorised into invasive & non-invasive treatment procedures. Currently available devices are MUSE, LINX reflux device, Stretta & GERD-X among others.
The devices are classified as invasive & non-invasive based on the procedures followed. Invasive procedures include LINX management system & MUSE while the non-invasive include EsophyX, Endostim, Stretta, Durasphere, GERD-X. The diagnostic devices include Bravo reflux management system & Digitrapper. The key players in the device market are Endogastric Solutions, Medigus Ltd., Medtronic Plc, Carbon Medical technologies, Johnson & Johnson etc. The gold standard in surgery for the treatment of GERD is Nissen Fundoplication.
Among all the geographical regions, North America has the highest GERD prevalence of 18.1-27.8%. In North America, the U.S. has the highest prevalence of 26.2%. Asia pacific has lower prevalence of 5-17%. The eastern countries have a lower prevalence rate than the western countries. North America is the highest revenue generating market with a value of $2.21 billion in 2016. The region is expected to grow at a CAGR of 0.3% for the forecast period from 2017 to 2023. RoW has the highest CAGR for the same forecast period.
Key Topics Covered:
1 Report Scope & Methodology
2 Market Overview
4 Drug Pipeline Analysis
5 Competitive Landscape
6 Industry Analysis
7 Global GERD Drug Market by Route of Administration, 2016-2023 (Qualitative)
8 Global GERD Drug Market by Dosage Form, 2016-2023 (Qualitative)
9 Global GERD Market by Drug Type, 2016-2023
10 Global GERD Market by Device Type, 2016-2023
11 Global GERD Drug and Devices Market by Region, 2016-2023
12 Company Profiles
- AstraZeneca PLC
- Boston Scientific Corporation
- Cempra Inc.
- Eisai Co., Ltd.
- EndoGastric Solutions Inc.
- EndoStim Inc.
- GlaxoSmithKline Plc
- Ironwood Pharmaceuticals, Inc.
- Jeil pharmaceutical Co. Ltd.
- Johnson & Johnson
- Mederi Therapeutics Inc.
- Medigus Ltd.
- Medtronic Inc.
- Merck & CO., Inc.
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Limited.
- Torax Medical
- Valeant Pharmaceuticals International, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/9r6jzx/global_gastro
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets